Testing version — LOERadar is in active testing. Features and data may change.

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM) | LOERadar

Viewing data from:

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

ANDA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM | A200465 | MYLAN PHARMACEUTICALS INC

11 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: CADUET

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Dec 5, 2013	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (11)

Sort:

#001 — EQ 2.5MG BASE;EQ 10MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Nov 29, 2013

No patent or exclusivity listings for this strength.

#002 — EQ 2.5MG BASE;EQ 20MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013

#003 — EQ 2.5MG BASE;EQ 40MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013

#004 — EQ 5MG BASE;EQ 10MG BASE

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013

#005 — EQ 5MG BASE;EQ 20MG BASE

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013

#006 — EQ 5MG BASE;EQ 40MG BASE

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013

#007 — EQ 5MG BASE;EQ 80MG BASE

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013

#008 — EQ 10MG BASE;EQ 10MG BASE

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013

#009 — EQ 10MG BASE;EQ 20MG BASE

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013

#010 — EQ 10MG BASE;EQ 40MG BASE

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013

#011 — EQ 10MG BASE;EQ 80MG BASE

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2013